TSX-V:KHRN - TSX Venture Exchange - CA49374L3065 - Common Stock - Currency: CAD
Taking everything into account, KHRN scores 2 out of 10 in our fundamental rating. KHRN was compared to 33 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of KHRN have multiple concerns. KHRN shows excellent growth, but is valued quite expensive already.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | N/A | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.51% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.91 | ||
Quick Ratio | 0.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
TSX-V:KHRN (5/5/2023, 7:00:00 PM)
0.04
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.45 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.27 | ||
P/tB | 0.36 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | N/A | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.51% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 143.78% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.91 | ||
Quick Ratio | 0.91 | ||
Altman-Z | -5.28 |